Make this your homepage
Business News
Home > Business News
Moderna taps into AWS to boost Covid-19 vaccine research
Moderna taps into AWS to boost Covid-19 vaccine research

Seattle, Aug 6 (TIWN) The biotechnology major Moderna which has entered the phase III clinical trials for its Covid-19 vaccine has selected Amazon Web Services (AWS) as its preferred Cloud partner as well as its standard for analytics and Machine Learning (ML) workloads.

Moderna is pioneering a new class of messenger RNA (mRNA) medicines.

Leveraging its mRNA platform and manufacturing facility with the AWS-powered research engine, Moderna delivered the first clinical batch of its vaccine candidate (mRNA-1273) against COVID-19 to the NIH for the Phase I trial, 42 days after the initial sequencing of the virus.

“The science behind mRNA medicines is advancing at a rapid pace, and building Moderna’s technology platform on AWS gives our scientists the insights, agility, and security they need to continue to lead in the industry,” said Stephane Bancel, Moderna’s Chief Executive Officer.

“With AWS, our researchers have the ability to quickly design and execute research experiments and rapidly uncover new insights to get potentially life-saving treatments into production faster,” Bancel said in a statement late on Wednesday.

Moderna has invented proprietary technologies and methods that run on AWS to create mRNA constructs that cells recognize as if they were produced in the body.

Add your Comment
Comments (0)

Special Articles

Saumen Sarkar Saumen Sarkar
Anirban Mitra Anirban Mitra